Skip to content
Screener

Myriad Genetics MYGN Q1 2026 earnings

Reported May 5, 2026 · After market close

Revenue$200.4MMiss by $2.0M
EPS-$0.09Miss by $0.03
Revenue estimate$202.4M
EPS estimate-$0.06

Next report

Nov 2, 2026 (in a month)
Revenue estimate$191.4M
EPS estimate-$0.16

Financials

Q1 2026

Income statement

See full
Revenue$200.4M+2.3%
Gross profit$137.6M+2.5%
Operating income-$30.7M-5.9%
Net income-$34.1M-34,000%
EPS (diluted)-$0.36—

Balance sheet

See full
Cash & equivalents$126.0M+24.8%
Total debt$211.5M+34.2%
Total equity$337.4M-52.1%
Total assets$673.7M-33.0%

Cash flow

See full
Operating cash flow-$15.7M+3.7%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$420.79M-48.0%
Enterprise value$506.29M-41.6%
P/S0.5×-0.5×

Profitability

See full
Gross margin70%0.0pp
Operating margin-46.9%-88.3pp
Net margin-48.2%-72.9pp

Returns & leverage

See full
Return on equity-76.7%-98.4pp
Debt / equity0.6×+0.4×
Current ratio2.4×+0.5×

Segments

By product

See full
Cancer Care Continuum$120.2M—
Prenatal Health$41.9M—
Mental Health$38.3M—

FAQ

When did Myriad Genetics report Q1 2026 earnings?
Myriad Genetics (MYGN) reported Q1 2026 earnings on May 5, 2026 after market close.
What were Myriad Genetics's Q1 2026 revenue and EPS?
Myriad Genetics reported revenue of $200.4M and eps of $-0.09 for Q1 2026.
Did Myriad Genetics beat estimates in Q1 2026?
Revenue missed the consensus estimate of $202.4M by $2.0M. EPS missed the consensus estimate of $-0.06 by $0.03.
How did Myriad Genetics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 2.3% from $195.9M a year earlier and eps declined 200.0% from $-0.03.
Where can I find Myriad Genetics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0000899923-26-000036) and the 10-Q periodic report (0000899923-26-000038) directly on SEC EDGAR. The filing index links above go to sec.gov.